Effectiveness and safety of anti-IL-5/Rα biologics in eosinophilic granulomatosis with polyangiitis: a two-year multicenter observational study

Effectiveness and safety of anti-IL-5/Rα biologics in eosinophilic granulomatosis with polyangiitis: a two-year multicenter observational study

BackgroundEosinophilic granulomatosis with polyangiitis (EGPA) is a rare vasculitis characterized by asthma, systemic manifestations, and blood and tissue eosinophilia.ObjectiveTo assess the effectiveness and safety of mepolizumab (anti-IL-5) and benralizumab (anti-IL-5Rα) in EGPA for 24 months.Meth...

Full description

Bibliographic Details
Main Authors: Santi Nolasco, Andrea Portacci, Raffaele Campisi, Enrico Buonamico, Corrado Pelaia, Alida Benfante, Massimo Triggiani, Giuseppe Spadaro, Maria Filomena Caiaffa, Giulia Scioscia, Aikaterini Detoraki, Giuseppe Valenti, Francesco Papia, Alessandra Tomasello, Nunzio Crimi, Nicola Scichilone, Girolamo Pelaia, Giovanna Elisiana Carpagnano, Claudia Crimi
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-06-01
Series:Frontiers in Immunology
Subjects:
EGPA
eosinophilic granulomatosis with polyangiitis
Churg-Strauss
mepolizumab
benralizumab
IL-5
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1204444/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1204444/full

Similar Items